Theravance Inc. (THRX): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Theravance ( THRX) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.1%. By the end of trading, Theravance rose $2.45 (6.3%) to $41.19 on heavy volume. Throughout the day, 2,518,142 shares of Theravance exchanged hands as compared to its average daily volume of 894,900 shares. The stock ranged in a price between $38.50-$41.80 after having opened the day at $38.55 as compared to the previous trading day's close of $38.74. Other companies within the Health Care sector that increased today were: GW Pharmaceuticals PLC ADR ( GWPH), up 53.2%, Genvec ( GNVC), up 43.7%, ERBA Diagnostics ( ERB), up 38.2% and Aratana Therapeutics ( PETX), up 15.3%.

Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system (CNS)/pain. Theravance has a market cap of $4.1 billion and is part of the drugs industry. Shares are up 69.9% year to date as of the close of trading on Wednesday. Currently there are 5 analysts that rate Theravance a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Theravance as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally high debt management risk.

On the negative front, Idera Pharmaceuticals ( IDRA), down 17.9%, Protalix BioTherapeutics ( PLX), down 15.1%, Natural Alternatives International ( NAII), down 9.0% and Inovio Pharmaceuticals ( INO), down 9.0% , were all laggards within the health care sector with Sanofi ( SNY) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Theravance (THRX) Highlighted As Weak On High Volume

Theravance (THRX) Flagged As Strong On High Volume

3 Sell-Rated Dividend Stocks: VER, BRS, THRX

The 10 Highest Dividend Health Care Stocks Are Not All Buys

5 Hated Stocks You Should Love This Earnings Season